Lilly's retatrutide shows large weight and A1C reductions in Phase 3 TRIUMPH‑2 and TRIUMPH‑3

Key highlights
  • Retatrutide produced up to -20.8% (-49.6 lb) mean weight loss at 80 weeks in TRIUMPH‑2 (adults with obesity/overweight and type 2 diabetes; n=1,152).
  • In TRIUMPH‑3 (severe obesity with established cardiovascular disease; n=1,949) mean weight loss reached -22.6% (-55.8 lb) at 80 weeks for the 12 mg dose.
  • Cardiovascular analyses: MACE‑5 HR 0.82 (95% CI 0.55–1.22) and MACE‑3 HR 1.12 (95% CI 0.64–1.96); risk‑factor changes included triglycerides -37.0% and hsCRP -51.2%.
  • Most common adverse events were gastrointestinal; discontinuation rates for adverse events ranged up to 13.5% vs ~4.8–4.9% for placebo. Lilly plans a BLA submission in Q1 2027.

Topline efficacy

In TRIUMPH‑2, a Phase 3, 80‑week trial randomizing 1,152 adults with obesity or overweight and type 2 diabetes to retatrutide 4 mg, 9 mg, 12 mg or placebo, mean weight loss at 80 weeks was -12.7% (-29.8 lb), -19.1% (-45.4 lb) and -20.8% (-49.6 lb) for 4 mg, 9 mg and 12 mg respectively, versus -4.0% (-9.3 lb) for placebo. A1C reductions reached up to -1.6% from a baseline of 7.7%.

Severe obesity with cardiovascular disease

In TRIUMPH‑3, an 80‑week trial in 1,949 participants with BMI ≥35 kg/m² and established cardiovascular disease, retatrutide 9 mg and 12 mg produced mean weight losses of -21.6% (-52.7 lb) and -22.6% (-55.8 lb) at 80 weeks, versus -3.2% (-7.7 lb) for placebo.

Cardiovascular events and risk factors

Pre‑specified time‑to‑event analyses showed 44 MACE‑5 events in pooled retatrutide arms versus 52 in placebo (HR 0.82; 95% CI 0.55–1.22). For MACE‑3 the HR was 1.12 (95% CI 0.64–1.96). Additional on‑treatment analyses yielded HRs of 0.73 (MACE‑5) and 0.92 (MACE‑3). The highest dose reduced triglycerides by 37.0%, non‑HDL cholesterol by 16.5%, systolic blood pressure by 9.3 mmHg, waist circumference by 19.0 cm and hsCRP by 51.2%.

Safety and regulatory path

The most common adverse events were gastrointestinal (diarrhea, nausea, constipation) and decreased appetite; reported incidence varied by dose. Discontinuation rates for adverse events ranged from 3.8% to 13.5% across retatrutide doses versus about 4.8–4.9% for placebo. Lilly is completing CMC data and plans to submit a Biologics License Application for retatrutide in Q1 2027.

Source: Lilly

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

29 September 2026
Lilly retatrutide shows large weight loss and A1C reductions in TRIUMPH-2

Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.

30 September 2026
Lilly's EloraTZP (eloralintide + tirzepatide) outperforms tirzepatide 15 mg in Phase 2b obesity and T2D trial

Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.

21 May 2026
Lilly’s retatrutide achieves up to 30% weight loss in Phase 3 TRIUMPH-1

Phase 3 TRIUMPH-1: three doses met endpoints at 80 weeks with dose-related, substantial weight loss. 104-week extension in BMI≥35 showed further loss; cardiometabolic markers improved; GI AEs common.

31 August 2026
Eli Lilly: Taltz plus Zepbound sustain improved psoriatic and metabolic outcomes at 52 weeks

Combination maintained or deepened psoriasis and psoriatic arthritis responses and reduced systemic inflammation while improving metabolic measures including BMI and HbA1c at one year versus Taltz alone.

28 August 2026
Eli Lilly’s Mounjaro approved by FDA to reduce cardiovascular risk in adults with type 2 diabetes

First GIP+GLP‑1 agonist authorised to lower major adverse cardiovascular events in high‑risk adults with type 2 diabetes; SURPASS‑CVOT enrolled >13,000 with ~4‑year median follow‑up.